tiprankstipranks
Enzon Pharmaceuticals (ENZN)
OTHER OTC:ENZN
Holding ENZN?
Track your performance easily

Enzon Pharmaceuticals (ENZN) Stock Price & Analysis

84 Followers

ENZN Stock Chart & Stats


Financials

Annual

Ownership Overview

<0.01%100.00%
Insiders
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

ENZN FAQ

What was Enzon Pharmaceuticals’s price range in the past 12 months?
Enzon Pharmaceuticals lowest stock price was $0.06 and its highest was $0.24 in the past 12 months.
    What is Enzon Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Enzon Pharmaceuticals’s upcoming earnings report date?
    Enzon Pharmaceuticals’s upcoming earnings report date is Nov 08, 2023 which is 380 days ago.
      How were Enzon Pharmaceuticals’s earnings last quarter?
      Enzon Pharmaceuticals released its earnings results on Aug 03, 2023. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
        Is Enzon Pharmaceuticals overvalued?
        According to Wall Street analysts Enzon Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Enzon Pharmaceuticals pay dividends?
          Enzon Pharmaceuticals pays a Notavailable dividend of $0.12 which represents an annual dividend yield of N/A. See more information on Enzon Pharmaceuticals dividends here
            What is Enzon Pharmaceuticals’s EPS estimate?
            Enzon Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Enzon Pharmaceuticals have?
            Enzon Pharmaceuticals has 74,214,600 shares outstanding.
              What happened to Enzon Pharmaceuticals’s price movement after its last earnings report?
              Enzon Pharmaceuticals reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Enzon Pharmaceuticals?
                Currently, no hedge funds are holding shares in ENZN
                ---

                Enzon Pharmaceuticals Stock Smart Score

                10
                Unlock Smart Score
                1
                2
                3
                4
                5
                6
                7
                8
                9
                10

                Technicals

                SMA
                Negative
                20 days / 200 days
                Momentum
                -40.00%
                12-Months-Change

                Fundamentals

                Return on Equity
                3.26%
                Trailing 12-Months
                Asset Growth
                0.59%
                Trailing 12-Months

                Company Description

                Enzon Pharmaceuticals

                Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Cormedix
                Cyclacel Pharmaceuticals
                Genprex
                CASI Pharmaceuticals
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis